Eledon Pharmaceuticals (ELDN) Free Cash Flow (2013 - 2026)

Eledon Pharmaceuticals (ELDN) has 14 years of Free Cash Flow data on file, last reported at -$22.6 million in Q1 2026.

• Quarterly Free Cash Flow fell 40.8% year-over-year to -$22.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$68.9 million (down 26.2% YoY) and the FY2025 annual result came in at -$62.3 million, down 31.88% from the prior year.
• Free Cash Flow eased to -$22.6 million in Q1 2026, from -$14.1 million in the prior quarter.
• In the past five years, Free Cash Flow ranged from a high of -$4.6 million in Q3 2022 to a low of -$22.6 million in Q1 2026.
• A 5-year average of -$11.8 million and a median of -$9.9 million in 2023 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2022 — Free Cash Flow jumped 35.56% — and 2023, when it plunged 168.02%.
• Tracing ELDN's Free Cash Flow over 5 years: stood at -$9.5 million in 2022, then rose by 3.68% to -$9.1 million in 2023, then plunged by 107.94% to -$19.0 million in 2024, then grew by 25.79% to -$14.1 million in 2025, then tumbled by 60.47% to -$22.6 million in 2026.
• The last three Free Cash Flow figures came in at -$22.6 million (Q1 2026), -$14.1 million (Q4 2025), and -$14.5 million (Q3 2025), per Business Quant data.